Global Market Study on Sickle Cell Disease Treatment: Sickle Cell Anaemia Anticipated to be the Most Lucrative Disease Type Segment Through 2025
Persistence Market Research has come up with a new report titled “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),” for the projected period of 8-years. According to this report, weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. We have not only captured the country price with the local currency but also the local currency figures is converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of country. Prices considered in the models are standardized based on the average dosage used per Sickle cell disease treatment per dosage in a year. Availability of branded off-patent equivalents have been taken into consideration while calculating prices.
We have used following parameters to estimate the global market size
Market sizing is done using our in-house epidemiology data based model to estimate sickle cell disease treatment market. We adopt bottom-up approach to forecast sickle cell disease treatment market globally. The following parameters are used to estimate the market size for the base year 2016:
Extensive secondary research has been carried out to understand the epidemiology of sickle cell disease, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, by referring published scientific literature from various databases such as the WHO, National Heart, Lung, and Blood Institute (NHLBI), PubMed, Springer, and Wiley among many others. We have also analyzed various companies’ annual report, investor presentation, SEC filings, 10k reports and press release operating in sickle cell disease treatment market to fetch substantial information about the market size, trends, opportunity, drivers, and restraints to analyze key players.
Report Inclusions and Exclusions
In this report, we have considered only those drugs that are administered for sickle cell disease treatment. The study includes drugs such as hydroxyurea, antibiotics, pain-relieving medications and others. The drugs considered in others segments are drugs that are administered based on patients conditions and also includes the newly FDA approved drug L-Glutamine for sickle cell disease treatment.
We have not included other therapies such as surgeries, blood transfusions, gene therapies and bone marrow transplantation etc. to calculate market value in this study. The market also do not includes any products from the drug type segment administered to patients of any other indications. The market value is calculated based on only the drug type (Hydroxyurea, Antibiotics, Pain-relieving medications, and other drugs) administered for sickle cell disease treatment.
Forecast Assumptions and Limitations
To forecast the market we have considered the following assumptions:
We have used following parameters to estimate the global market size
Market sizing is done using our in-house epidemiology data based model to estimate sickle cell disease treatment market. We adopt bottom-up approach to forecast sickle cell disease treatment market globally. The following parameters are used to estimate the market size for the base year 2016:
- Country level data for prevalence and incidence rate for calculating base population
- Diagnosis rate
- Treatment rate and percentage adoption of currently available treatment options in various stages of the disease for calculating target population
- Average cost of drug treatment cycle associated with the each treatment option
- Average cost of each cycle is then multiplied by average number of cycles taken by patients for all drug type (differs from drug to drug) in an year
- We have used a number of sources to present a detailed analysis of the global sickle cell disease treatment market
Extensive secondary research has been carried out to understand the epidemiology of sickle cell disease, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, by referring published scientific literature from various databases such as the WHO, National Heart, Lung, and Blood Institute (NHLBI), PubMed, Springer, and Wiley among many others. We have also analyzed various companies’ annual report, investor presentation, SEC filings, 10k reports and press release operating in sickle cell disease treatment market to fetch substantial information about the market size, trends, opportunity, drivers, and restraints to analyze key players.
Report Inclusions and Exclusions
In this report, we have considered only those drugs that are administered for sickle cell disease treatment. The study includes drugs such as hydroxyurea, antibiotics, pain-relieving medications and others. The drugs considered in others segments are drugs that are administered based on patients conditions and also includes the newly FDA approved drug L-Glutamine for sickle cell disease treatment.
We have not included other therapies such as surgeries, blood transfusions, gene therapies and bone marrow transplantation etc. to calculate market value in this study. The market also do not includes any products from the drug type segment administered to patients of any other indications. The market value is calculated based on only the drug type (Hydroxyurea, Antibiotics, Pain-relieving medications, and other drugs) administered for sickle cell disease treatment.
Forecast Assumptions and Limitations
To forecast the market we have considered the following assumptions:
- Growth in diagnosis and treatment rate
- Change in price of drugs
- Adoption curve for available treatment
- Impact of launch of new combination regimen which are in late stage of development
- Forecasting has been done on a static base and only currently approved products have been taken into consideration for calculating the actual size of the treatment market
- Our clients should note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting is done on our internal proprietary model which also uses different macro-economic factors and industry based demand driving factors that are impacting the market and its forecast trends apart from disease related factors.
1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. MARKET INTRODUCTION
2.1. Market Definition
2.2. Market Taxonomy
3. MARKET VIEW POINT
3.1. Opportunity Analysis
3.2. Global Market Drivers
3.2.1. Macroeconomic Drivers
3.2.2. Demand-side Drivers
3.2.3. Supply-side Drivers
3.3. Global Market Restraints
3.4. Global Market Trends
3.5. Epidemiology data of Sickle cell Disease, 2015
3.6. Epidemiology data of Sickle cell Disease < 5 years, 2015
3.7. Product Pipeline Analysis
4. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
4.5.1. Hydroxyurea
4.5.2. Antibiotics
4.5.3. Pain-relieving Medications
4.5.4. Others
4.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
4.6.1. Hydroxyurea
4.6.2. Antibiotics
4.6.3. Pain-relieving Medications
4.6.4. Others
4.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
4.7.1. Sickle cell anemia
4.7.2. Sickle hemoglobin C disease
4.7.3. Sickle beta thalassemia
4.7.4. Others
4.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
4.8.1. Sickle cell anemia
4.8.2. Sickle hemoglobin C disease
4.8.3. Sickle beta thalassemia
4.8.4. Others
4.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
4.9.1. Hospital Pharmacies
4.9.2. Retail Pharmacies
4.9.3. Online Pharmacies
4.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
4.10.1. Hospital Pharmacies
4.10.2. Retail Pharmacies
4.10.3. Online Pharmacies
4.11.Drivers and Restraints: Impact Analysis
4.12.Market Attractiveness Analysis
4.12.1. By Country
4.12.2. By Drug Type
4.12.3. By Disease Type
4.12.4. By Distribution Channel
5. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
5.5.1. Hydroxyurea
5.5.2. Antibiotics
5.5.3. Pain-relieving Medications
5.5.4. Others
5.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
5.6.1. Hydroxyurea
5.6.2. Antibiotics
5.6.3. Pain-relieving Medications
5.6.4. Others
5.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
5.7.1. Sickle cell anemia
5.7.2. Sickle hemoglobin C disease
5.7.3. Sickle beta thalassemia
5.7.4. Others
5.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
5.8.1. Sickle cell anemia
5.8.2. Sickle hemoglobin C disease
5.8.3. Sickle beta thalassemia
5.8.4. Others
5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
5.9.1. Hospital Pharmacies
5.9.2. Retail Pharmacies
5.9.3. Online Pharmacies
5.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
5.10.1. Hospital Pharmacies
5.10.2. Retail Pharmacies
5.10.3. Online Pharmacies
5.11.Drivers and Restraints: Impact Analysis
5.12.Market Attractiveness Analysis
5.12.1. By Country
5.12.2. By Drug Type
5.12.3. By Disease Type
5.12.4. By Distribution Channel
6. EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. France
6.3.3. U.K.
6.3.4. Spain
6.3.5. Italy
6.3.6. Russia
6.3.7. Rest of Europe
6.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Spain
6.4.5. Italy
6.4.6. Russia
6.4.7. Rest of Europe
6.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
6.5.1. Hydroxyurea
6.5.2. Antibiotics
6.5.3. Pain-relieving Medications
6.5.4. Others
6.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
6.6.1. Hydroxyurea
6.6.2. Antibiotics
6.6.3. Pain-relieving Medications
6.6.4. Others
6.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
6.7.1. Sickle cell anemia
6.7.2. Sickle hemoglobin C disease
6.7.3. Sickle beta thalassemia
6.7.4. Others
6.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
6.8.1. Sickle cell anemia
6.8.2. Sickle hemoglobin C disease
6.8.3. Sickle beta thalassemia
6.8.4. Others
6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
6.9.1. Hospital Pharmacies
6.9.2. Retail Pharmacies
6.9.3. Online Pharmacies
6.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Online Pharmacies
6.11.Drivers and Restraints: Impact Analysis
6.12.Market Attractiveness Analysis
6.12.1. By Country
6.12.2. By Drug Type
6.12.3. By Disease Type
6.12.4. By Distribution Channel
7. ASIA PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. Australia and New Zealand
7.3.5. ASEAN
7.3.6. Rest of ASIA PACIFIC
7.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
7.4.1. China
7.4.2. India
7.4.3. Japan
7.4.4. Australia and New Zealand
7.4.5. ASEAN
7.4.6. Rest of Asia Pacific
7.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
7.5.1. Hydroxyurea
7.5.2. Antibiotics
7.5.3. Pain-relieving Medications
7.5.4. Others
7.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
7.6.1. Hydroxyurea
7.6.2. Antibiotics
7.6.3. Pain-relieving Medications
7.6.4. Others
7.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
7.7.1. Sickle cell anemia
7.7.2. Sickle hemoglobin C disease
7.7.3. Sickle beta thalassemia
7.7.4. Others
7.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
7.8.1. Sickle cell anemia
7.8.2. Sickle hemoglobin C disease
7.8.3. Sickle beta thalassemia
7.8.4. Others
7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
7.9.1. Hospital Pharmacies
7.9.2. Retail Pharmacies
7.9.3. Online Pharmacies
7.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Online Pharmacies
7.11.Drivers and Restraints: Impact Analysis
7.12.Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Type
7.12.3. By Disease Type
7.12.4. By Distribution Channel
8. MEA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.3.1. GCC Countries
8.3.2. South Africa
8.3.3. Rest of MEA
8.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
8.4.1. GCC Countries
8.4.2. South Africa
8.4.3. Rest of MEA
8.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
8.5.1. Hydroxyurea
8.5.2. Antibiotics
8.5.3. Pain-relieving Medications
8.5.4. Others
8.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
8.6.1. Hydroxyurea
8.6.2. Antibiotics
8.6.3. Pain-relieving Medications
8.6.4. Others
8.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
8.7.1. Sickle cell anemia
8.7.2. Sickle hemoglobin C disease
8.7.3. Sickle beta thalassemia
8.7.4. Others
8.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
8.8.1. Sickle cell anemia
8.8.2. Sickle hemoglobin C disease
8.8.3. Sickle beta thalassemia
8.8.4. Others
8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
8.9.1. Hospital Pharmacies
8.9.2. Retail Pharmacies
8.9.3. Online Pharmacies
8.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Online Pharmacies
8.11.Drivers and Restraints: Impact Analysis
8.12.Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Type
8.12.3. By Disease Type
8.12.4. By Distribution Channel
9. FORECAST ASSUMPTIONS
10. COMPETITION LANDSCAPE
10.1.Competition Dashboard
10.2.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
10.2.1. AstraZeneca Plc.
10.2.2. Eli Lilly and Company
10.2.3. Bristol-Myers Squibb Company
10.2.4. Novartis AG
10.2.5. Pfizer Inc.
10.2.6. Baxter International Inc.
10.2.7. Emmaus Life Sciences, Inc.
10.2.8. Bluebird bio, Inc.
10.2.9. Global Blood Therapeutics Inc.
10.2.10. Sangamo Therapeutics, Inc.
10.2.11. Acceleron Pharma, Inc.
10.2.12. Arena Pharmaceuticals, Inc.
10.2.13. Alnylam Pharmaceuticals, Inc.
11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY REGION
11.1.Introduction / Key Findings
11.2.Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
11.2.1. North America
11.2.2. Latin America
11.2.3. Europe
11.2.4. Asia Pacific
11.2.5. MEA
11.3.Market Size (US$ Mn) Forecast By Region, 2017-2025
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. MEA
11.4.Market Attractiveness Analysis By Region
12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DRUG TYPE
12.1.Introduction
12.2.Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
12.2.1. Hydroxyurea
12.2.2. Antibiotics
12.2.3. Pain-relieving Medications
12.2.4. Others
12.3.Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
12.3.1. Hydroxyurea
12.3.2. Antibiotics
12.3.3. Pain-relieving Medications
12.3.4. Others
12.4.Market Attractiveness Analysis By Drug Type
13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISEASE TYPE
13.1.Introduction
13.2.Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
13.2.1. Sickle cell anemia
13.2.2. Sickle hemoglobin C disease
13.2.3. Sickle beta thalassemia
13.2.4. Others
13.3.Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
13.3.1. Sickle cell anemia
13.3.2. Sickle hemoglobin C disease
13.3.3. Sickle beta thalassemia
13.3.4. Others
13.4.Market Attractiveness Analysis By Disease Type
14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISTRIBUTION CHANNEL
14.1.Introduction
14.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
14.2.1. Hospital Pharmacies
14.2.2. Retail Pharmacies
14.2.3. Online pharmacies
14.3.Market Size (US$ Mn) and Forecast By Distribution Channel, 2017-2025
14.3.1. Hospital Pharmacies
14.3.2. Retail Pharmacies
14.3.3. Online pharmacies
14.4.Market Attractive Analysis By Distribution Channel
15. GLOBAL MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
15.1.Market Size and Y-o-Y Growth
15.2.Absolute $ Opportunity
16. RESEARCH METHODOLOG
1.1. Market Overview
1.2. Market Analysis
1.3. PMR Analysis and Recommendations
1.4. Wheel of Fortune
2. MARKET INTRODUCTION
2.1. Market Definition
2.2. Market Taxonomy
3. MARKET VIEW POINT
3.1. Opportunity Analysis
3.2. Global Market Drivers
3.2.1. Macroeconomic Drivers
3.2.2. Demand-side Drivers
3.2.3. Supply-side Drivers
3.3. Global Market Restraints
3.4. Global Market Trends
3.5. Epidemiology data of Sickle cell Disease, 2015
3.6. Epidemiology data of Sickle cell Disease < 5 years, 2015
3.7. Product Pipeline Analysis
4. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
4.5.1. Hydroxyurea
4.5.2. Antibiotics
4.5.3. Pain-relieving Medications
4.5.4. Others
4.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
4.6.1. Hydroxyurea
4.6.2. Antibiotics
4.6.3. Pain-relieving Medications
4.6.4. Others
4.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
4.7.1. Sickle cell anemia
4.7.2. Sickle hemoglobin C disease
4.7.3. Sickle beta thalassemia
4.7.4. Others
4.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
4.8.1. Sickle cell anemia
4.8.2. Sickle hemoglobin C disease
4.8.3. Sickle beta thalassemia
4.8.4. Others
4.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
4.9.1. Hospital Pharmacies
4.9.2. Retail Pharmacies
4.9.3. Online Pharmacies
4.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
4.10.1. Hospital Pharmacies
4.10.2. Retail Pharmacies
4.10.3. Online Pharmacies
4.11.Drivers and Restraints: Impact Analysis
4.12.Market Attractiveness Analysis
4.12.1. By Country
4.12.2. By Drug Type
4.12.3. By Disease Type
4.12.4. By Distribution Channel
5. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Rest of Latin America
5.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
5.5.1. Hydroxyurea
5.5.2. Antibiotics
5.5.3. Pain-relieving Medications
5.5.4. Others
5.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
5.6.1. Hydroxyurea
5.6.2. Antibiotics
5.6.3. Pain-relieving Medications
5.6.4. Others
5.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
5.7.1. Sickle cell anemia
5.7.2. Sickle hemoglobin C disease
5.7.3. Sickle beta thalassemia
5.7.4. Others
5.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
5.8.1. Sickle cell anemia
5.8.2. Sickle hemoglobin C disease
5.8.3. Sickle beta thalassemia
5.8.4. Others
5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
5.9.1. Hospital Pharmacies
5.9.2. Retail Pharmacies
5.9.3. Online Pharmacies
5.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
5.10.1. Hospital Pharmacies
5.10.2. Retail Pharmacies
5.10.3. Online Pharmacies
5.11.Drivers and Restraints: Impact Analysis
5.12.Market Attractiveness Analysis
5.12.1. By Country
5.12.2. By Drug Type
5.12.3. By Disease Type
5.12.4. By Distribution Channel
6. EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
6.3.1. Germany
6.3.2. France
6.3.3. U.K.
6.3.4. Spain
6.3.5. Italy
6.3.6. Russia
6.3.7. Rest of Europe
6.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Spain
6.4.5. Italy
6.4.6. Russia
6.4.7. Rest of Europe
6.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
6.5.1. Hydroxyurea
6.5.2. Antibiotics
6.5.3. Pain-relieving Medications
6.5.4. Others
6.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
6.6.1. Hydroxyurea
6.6.2. Antibiotics
6.6.3. Pain-relieving Medications
6.6.4. Others
6.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
6.7.1. Sickle cell anemia
6.7.2. Sickle hemoglobin C disease
6.7.3. Sickle beta thalassemia
6.7.4. Others
6.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
6.8.1. Sickle cell anemia
6.8.2. Sickle hemoglobin C disease
6.8.3. Sickle beta thalassemia
6.8.4. Others
6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
6.9.1. Hospital Pharmacies
6.9.2. Retail Pharmacies
6.9.3. Online Pharmacies
6.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacies
6.10.3. Online Pharmacies
6.11.Drivers and Restraints: Impact Analysis
6.12.Market Attractiveness Analysis
6.12.1. By Country
6.12.2. By Drug Type
6.12.3. By Disease Type
6.12.4. By Distribution Channel
7. ASIA PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. Australia and New Zealand
7.3.5. ASEAN
7.3.6. Rest of ASIA PACIFIC
7.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
7.4.1. China
7.4.2. India
7.4.3. Japan
7.4.4. Australia and New Zealand
7.4.5. ASEAN
7.4.6. Rest of Asia Pacific
7.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
7.5.1. Hydroxyurea
7.5.2. Antibiotics
7.5.3. Pain-relieving Medications
7.5.4. Others
7.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
7.6.1. Hydroxyurea
7.6.2. Antibiotics
7.6.3. Pain-relieving Medications
7.6.4. Others
7.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
7.7.1. Sickle cell anemia
7.7.2. Sickle hemoglobin C disease
7.7.3. Sickle beta thalassemia
7.7.4. Others
7.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
7.8.1. Sickle cell anemia
7.8.2. Sickle hemoglobin C disease
7.8.3. Sickle beta thalassemia
7.8.4. Others
7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
7.9.1. Hospital Pharmacies
7.9.2. Retail Pharmacies
7.9.3. Online Pharmacies
7.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacies
7.10.3. Online Pharmacies
7.11.Drivers and Restraints: Impact Analysis
7.12.Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Type
7.12.3. By Disease Type
7.12.4. By Distribution Channel
8. MEA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
8.3.1. GCC Countries
8.3.2. South Africa
8.3.3. Rest of MEA
8.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
8.4.1. GCC Countries
8.4.2. South Africa
8.4.3. Rest of MEA
8.5. Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
8.5.1. Hydroxyurea
8.5.2. Antibiotics
8.5.3. Pain-relieving Medications
8.5.4. Others
8.6. Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
8.6.1. Hydroxyurea
8.6.2. Antibiotics
8.6.3. Pain-relieving Medications
8.6.4. Others
8.7. Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
8.7.1. Sickle cell anemia
8.7.2. Sickle hemoglobin C disease
8.7.3. Sickle beta thalassemia
8.7.4. Others
8.8. Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
8.8.1. Sickle cell anemia
8.8.2. Sickle hemoglobin C disease
8.8.3. Sickle beta thalassemia
8.8.4. Others
8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
8.9.1. Hospital Pharmacies
8.9.2. Retail Pharmacies
8.9.3. Online Pharmacies
8.10.Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacies
8.10.3. Online Pharmacies
8.11.Drivers and Restraints: Impact Analysis
8.12.Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Type
8.12.3. By Disease Type
8.12.4. By Distribution Channel
9. FORECAST ASSUMPTIONS
10. COMPETITION LANDSCAPE
10.1.Competition Dashboard
10.2.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
10.2.1. AstraZeneca Plc.
10.2.2. Eli Lilly and Company
10.2.3. Bristol-Myers Squibb Company
10.2.4. Novartis AG
10.2.5. Pfizer Inc.
10.2.6. Baxter International Inc.
10.2.7. Emmaus Life Sciences, Inc.
10.2.8. Bluebird bio, Inc.
10.2.9. Global Blood Therapeutics Inc.
10.2.10. Sangamo Therapeutics, Inc.
10.2.11. Acceleron Pharma, Inc.
10.2.12. Arena Pharmaceuticals, Inc.
10.2.13. Alnylam Pharmaceuticals, Inc.
11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY REGION
11.1.Introduction / Key Findings
11.2.Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
11.2.1. North America
11.2.2. Latin America
11.2.3. Europe
11.2.4. Asia Pacific
11.2.5. MEA
11.3.Market Size (US$ Mn) Forecast By Region, 2017-2025
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. MEA
11.4.Market Attractiveness Analysis By Region
12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DRUG TYPE
12.1.Introduction
12.2.Historical Market Size (US$ Mn) Analysis By Drug Type, 2012–2016
12.2.1. Hydroxyurea
12.2.2. Antibiotics
12.2.3. Pain-relieving Medications
12.2.4. Others
12.3.Market Size (US$ Mn) Forecast By Drug Type, 2017–2025
12.3.1. Hydroxyurea
12.3.2. Antibiotics
12.3.3. Pain-relieving Medications
12.3.4. Others
12.4.Market Attractiveness Analysis By Drug Type
13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISEASE TYPE
13.1.Introduction
13.2.Historical Market Size (US$ Mn) Analysis By Disease Type, 2012–2016
13.2.1. Sickle cell anemia
13.2.2. Sickle hemoglobin C disease
13.2.3. Sickle beta thalassemia
13.2.4. Others
13.3.Market Size (US$ Mn) and Forecast, By Disease Type, 2017–2025
13.3.1. Sickle cell anemia
13.3.2. Sickle hemoglobin C disease
13.3.3. Sickle beta thalassemia
13.3.4. Others
13.4.Market Attractiveness Analysis By Disease Type
14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025, BY DISTRIBUTION CHANNEL
14.1.Introduction
14.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
14.2.1. Hospital Pharmacies
14.2.2. Retail Pharmacies
14.2.3. Online pharmacies
14.3.Market Size (US$ Mn) and Forecast By Distribution Channel, 2017-2025
14.3.1. Hospital Pharmacies
14.3.2. Retail Pharmacies
14.3.3. Online pharmacies
14.4.Market Attractive Analysis By Distribution Channel
15. GLOBAL MARKET ANALYSIS 2012–2016 AND FORECAST 2017–2025
15.1.Market Size and Y-o-Y Growth
15.2.Absolute $ Opportunity
16. RESEARCH METHODOLOG
LIST OF TABLES
Table 1: Epidemiology data of Sickle cell Disease 2015
Table 2: Epidemiology data of Sickle cell Disease < 5 years 2015
Table 3: Pipeline Products
Table 4: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 5: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 6: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 7: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 8: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 9: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 10: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 11: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 12: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 13: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 14: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 15: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 16: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 17: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 18: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 19: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region
Table 20: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast, 2017-2025, By Drug Type
Table 21: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast, 2017-2025, By Disease Type
Table 22: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025, By Distribution Channel
Table 1: Epidemiology data of Sickle cell Disease 2015
Table 2: Epidemiology data of Sickle cell Disease < 5 years 2015
Table 3: Pipeline Products
Table 4: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 5: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 6: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 7: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 8: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 9: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 10: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 11: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 12: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 13: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 14: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 15: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 16: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 17: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Drug Type
Table 18: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Disease Type
Table 19: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region
Table 20: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast, 2017-2025, By Drug Type
Table 21: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast, 2017-2025, By Disease Type
Table 22: Global Sickle Cell Disease Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025, By Distribution Channel
LIST OF FIGURES
Figure 1: Global Sickle Cell Disease Treatment Market Revenue Share, By Drug Type (2017)
Figure 2: Global Sickle Cell Disease Treatment Market Revenue Share, By Indication (2017)
Figure 3: Global Sickle Cell Disease Treatment Market Revenue Share, By Distribution Channel (2017)
Figure 4: North America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 5: North America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 6: North America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 7: North America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 8: North America Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 9: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 10: North America Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 11: North America Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 12: North America Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 13: North America Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 14: North America Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 15: North America Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 16: North America Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 17: North America Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 18: North America Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 19: North America Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 20: North America Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 21: North America Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 22: North America Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 23: North America Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 24: North America Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 25: North America Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 26: North America Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 27: North America Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 28: North America Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 29: North America Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 30: North America Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 31: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 32: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 33: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 34: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 35: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 36: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 37: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 38: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 40: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 41: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 42: Latin America Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 43: Latin America Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 44: Latin America Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 45: Latin America Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 46: Latin America Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 47: Latin America Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 48: Latin America Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 49: Latin America Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 50: Latin America Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 51: Latin America Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 52: Latin America Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 53: Latin America Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 54: Latin America Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 55: Latin America Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 56: Latin America Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 57: Latin America Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 58: Latin America Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 59: Latin America Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 60: Latin America Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 61: Latin America Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 62: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 63: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 64: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 65: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 66: Europe Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 67: Europe Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 68: Europe Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 69: Europe Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 70: Europe Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 71: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 72: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 73: Europe Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 74: Europe Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 75: Europe Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 76: Europe Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 77: Europe Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 78: Europe Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 79: Europe Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 80: Europe Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 81: Europe Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 82: Europe Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 83: Europe Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 84: Europe Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 85: Europe Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 86: Europe Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 87: Europe Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 88: Europe Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 89: Europe Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 90: Europe Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 91: Europe Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 92: Europe Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 93: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 94: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 95: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 96: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 97: APAC Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 98: APAC Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 99: APAC Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 100: APAC Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 101: APAC Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 102: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 103: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 104: APAC Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 105: APAC Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 106: APAC Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 107: APAC Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 108: APAC Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 109: APAC Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 110: APAC Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 111: APAC Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 112: APAC Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 113: APAC Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 114: APAC Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 115: APAC Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 116: APAC Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 117: APAC Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 118: APAC Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 119: APAC Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 120: APAC Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 121: APAC Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 122: APAC Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 123: APAC Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 124: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 125: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 126: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 127: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 128: MEA Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 129: MEA Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 130: MEA Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 131: MEA Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 132: MEA Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 133: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 134: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 135: MEA Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 136: MEA Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 137: MEA Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 138: MEA Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 139: MEA Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 140: MEA Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 141: MEA Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 142: MEA Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 143: MEA Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 144: MEA Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 145: MEA Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 146: MEA Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 147: MEA Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 148: MEA Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 149: MEA Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 150: MEA Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 151: MEA Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 152: MEA Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 153: MEA Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 154: MEA Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 155: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 156: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 157: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 158: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 159: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Region, 2017–2025
Figure 160: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Drug Type, 2017–2025
Figure 161: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Disease Type, 2017–2025
Figure 162: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Distribution Channel, 2017–2025
Figure 163: Global Sickle Cell Disease Treatment Market Value Analysis and Forecast, 2016–2025 (US$ Mn)
Figure 164: Global Sickle Cell Disease Treatment Market Absolute $ Opportunity (US$ Mn), 2012–2016
Figure 165: Global Sickle Cell Disease Treatment Market Absolute $ Opportunity (US$ Mn), 2016–2025
Figure 1: Global Sickle Cell Disease Treatment Market Revenue Share, By Drug Type (2017)
Figure 2: Global Sickle Cell Disease Treatment Market Revenue Share, By Indication (2017)
Figure 3: Global Sickle Cell Disease Treatment Market Revenue Share, By Distribution Channel (2017)
Figure 4: North America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 5: North America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 6: North America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 7: North America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 8: North America Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 9: North America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 10: North America Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 11: North America Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 12: North America Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 13: North America Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 14: North America Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 15: North America Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 16: North America Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 17: North America Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 18: North America Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 19: North America Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 20: North America Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 21: North America Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 22: North America Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 23: North America Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 24: North America Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 25: North America Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 26: North America Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 27: North America Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 28: North America Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 29: North America Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 30: North America Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 31: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 32: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 33: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 34: North America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 35: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 36: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 37: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 38: Latin America Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 40: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 41: Latin America Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 42: Latin America Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 43: Latin America Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 44: Latin America Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 45: Latin America Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 46: Latin America Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 47: Latin America Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 48: Latin America Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 49: Latin America Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 50: Latin America Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 51: Latin America Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 52: Latin America Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 53: Latin America Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 54: Latin America Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 55: Latin America Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 56: Latin America Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 57: Latin America Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 58: Latin America Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 59: Latin America Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 60: Latin America Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 61: Latin America Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 62: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 63: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 64: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 65: Latin America Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 66: Europe Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 67: Europe Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 68: Europe Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 69: Europe Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 70: Europe Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 71: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 72: Europe Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 73: Europe Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 74: Europe Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 75: Europe Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 76: Europe Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 77: Europe Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 78: Europe Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 79: Europe Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 80: Europe Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 81: Europe Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 82: Europe Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 83: Europe Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 84: Europe Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 85: Europe Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 86: Europe Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 87: Europe Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 88: Europe Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 89: Europe Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 90: Europe Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 91: Europe Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 92: Europe Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 93: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 94: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 95: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 96: Europe Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 97: APAC Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 98: APAC Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 99: APAC Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 100: APAC Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 101: APAC Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 102: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 103: APAC Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 104: APAC Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 105: APAC Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 106: APAC Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 107: APAC Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 108: APAC Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 109: APAC Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 110: APAC Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 111: APAC Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 112: APAC Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 113: APAC Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 114: APAC Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 115: APAC Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 116: APAC Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 117: APAC Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 118: APAC Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 119: APAC Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 120: APAC Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 121: APAC Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 122: APAC Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 123: APAC Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 124: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 125: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 126: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 127: APAC Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 128: MEA Sickle Cell Disease Treatment Market Value Share (%) By Drug Type (2017)
Figure 129: MEA Sickle Cell Disease Treatment Market Value Share (%) By Distribution Channel (2017)
Figure 130: MEA Sickle Cell Disease Treatment Market Value Share (%) By Disease Indication (2017)
Figure 131: MEA Sickle Cell Disease Treatment Market Value Share (%) By Country (2017)
Figure 132: MEA Sickle Cell Disease Treatment Market Value (US$ Mn) & Forecast 2017 & 2025
Figure 133: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) Analysis, 2012–2016
Figure 134: MEA Sickle Cell Disease Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 135: MEA Hydroxyurea Market Size (US$ Mn) Analysis, 2012–2016
Figure 136: MEA Hydroxyurea Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 137: MEA Antibiotics Market Size (US$ Mn) Analysis, 2012–2016
Figure 138: MEA Antibiotics Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 139: MEA Pain-relieving Medications Market Size (US$ Mn) Analysis, 2012–2016
Figure 140: MEA Pain-relieving Medications Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 141: MEA Others Market Size (US$ Mn) Analysis, 2012–2016
Figure 142: MEA Others Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 143: MEA Sickle cell anemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 144: MEA Sickle cell anemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 145: MEA Sickle Hemoglobin C Disease Market Size (US$ Mn) Analysis, 2012–2016
Figure 146: MEA Sickle Hemoglobin C Disease Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 147: MEA Sickle Beta Thalassemia Market Size (US$ Mn) Analysis, 2012–2016
Figure 148: MEA Sickle Beta Thalassemia Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 149: MEA Hospital Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 150: MEA Hospital Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 151: MEA Retail Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 152: MEA Retail Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 153: MEA Online Pharmacies Market Size (US$ Mn) Analysis, 2012–2016
Figure 154: MEA Online Pharmacies Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 155: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Drug Type
Figure 156: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Disease Type
Figure 157: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 158: MEA Sickle Cell Disease Treatment Market Attractiveness Analysis, By Country
Figure 159: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Region, 2017–2025
Figure 160: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Drug Type, 2017–2025
Figure 161: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Disease Type, 2017–2025
Figure 162: Global Sickle Cell Disease Treatment Market Attractiveness Analysis By Distribution Channel, 2017–2025
Figure 163: Global Sickle Cell Disease Treatment Market Value Analysis and Forecast, 2016–2025 (US$ Mn)
Figure 164: Global Sickle Cell Disease Treatment Market Absolute $ Opportunity (US$ Mn), 2012–2016
Figure 165: Global Sickle Cell Disease Treatment Market Absolute $ Opportunity (US$ Mn), 2016–2025
